Equity Profile
Pre-Earnings Brief
Novartis AG (NVS) is a global healthcare company focused on developing and manufacturing innovative pharmaceuticals. With a market cap of $280 billion, it plays a significant role in the healthcare sector, addressing various medical needs and advancing treatments.
Earnings Per Share (EPS)
EPS is a key indicator of a company's profitability and is closely watched by investors.
Revenue Growth
Revenue growth reflects the company's ability to expand its market presence and product sales.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
75%
Avg EPS Surprise
+3.66%
Avg Stock Reaction
-1.57%
In Q1-2026, Novartis reported an EPS of $1.99, which was lower than the expected $2.11, resulting in a negative surprise of 5.6%. Despite this, the stock saw a modest increase of 0.91% the following day.
Management Promises & Guidance
Overall, expectations for Novartis are mixed, with some investors hoping for a rebound in EPS and revenue growth after a recent miss. The market will be keenly observing any updates on the company's drug pipeline.
Bull Case
If Novartis can demonstrate strong pipeline advancements and better-than-expected EPS, it could restore investor confidence and drive the stock higher.
Bear Case
Conversely, if the company continues to miss EPS estimates and fails to provide positive updates on its pipeline, it may face further downward pressure on its stock.
Earnings Per Share (EPS)
N/AEPS is a key indicator of a company's profitability and is closely watched by investors.
Revenue Growth
N/ARevenue growth reflects the company's ability to expand its market presence and product sales.
Pipeline Developments
N/AUpdates on drug pipeline progress can significantly impact future revenue and market perception.
Expectations
The print will turn on these two things.
Q1
What is the updated EPS forecast for Q2-2026?
The EPS forecast will be crucial in assessing whether Novartis can recover from its recent earnings miss and regain investor confidence.
Q2
What progress has been made on key drugs in the pipeline?
Updates on the drug pipeline can significantly influence future revenue potential and market sentiment.
Edge
Why consensus could be wrong
The Street may be underestimating the potential for a rebound in Novartis' EPS, given the historical trend of recovery following earnings misses.
Supporting Evidence
75% of the time, Novartis has beaten EPS estimates in the past, suggesting potential for a positive surprise.
The options market is pricing in a significant move, indicating that investors are expecting volatility and potential positive news.
Key Risk
If the EPS comes in above $2.15, it could challenge the current cautious sentiment and shift the narrative.
Edge
Pre-commit to what would confirm each case.
The core thesis revolves around Novartis' ability to meet or exceed EPS expectations and provide positive updates on its drug pipeline.
Bull Confirmed If
A positive EPS of $2.15 or higher would confirm the bull case and suggest a recovery in profitability.
Bear Confirmed If
An EPS below $1.90 would confirm the bear case and raise concerns about the company's financial health.
Pre-Earnings Positioning
Implied Move
±6.02%
Historical Avg
±2.5%
The options market is pricing in a significant potential move of over 6% around the earnings report, indicating heightened uncertainty among investors.
Options are pricing ±6.0% while NVS has averaged ±2.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.2%
30d HV
21.1%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
n=30Fade rate: 6 of 19 (32%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 19 (68%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.5%, with a raw directional average of +3.2% (modestly positive historical bias).
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Novartis beats EPS estimates and raises guidance, history suggests the stock could see an average one-day move of +1.5%.
In-Line / Cautious
If the results are in line with expectations but management provides cautious commentary, the stock may experience muted movement.
Miss
If Novartis misses EPS estimates again, history suggests a potential average one-day decline of -1.76%.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Domino's Pizza, Inc.